Burney Co. Has $637,000 Holdings in Zoetis Inc. $ZTS

Burney Co. lifted its holdings in Zoetis Inc. (NYSE:ZTS) by 14.6% in the 2nd quarter, Holdings Channel reports. The firm owned 4,087 shares of the company’s stock after buying an additional 520 shares during the quarter. Burney Co.’s holdings in Zoetis were worth $637,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also modified their holdings of ZTS. Nova Wealth Management Inc. acquired a new stake in shares of Zoetis in the 1st quarter valued at $25,000. 1248 Management LLC acquired a new stake in shares of Zoetis in the 1st quarter valued at $27,000. Saudi Central Bank acquired a new stake in shares of Zoetis in the 1st quarter valued at $29,000. Cornerstone Planning Group LLC lifted its stake in shares of Zoetis by 79.3% in the 1st quarter. Cornerstone Planning Group LLC now owns 199 shares of the company’s stock valued at $30,000 after purchasing an additional 88 shares during the last quarter. Finally, REAP Financial Group LLC lifted its position in Zoetis by 201.5% during the 2nd quarter. REAP Financial Group LLC now owns 196 shares of the company’s stock worth $31,000 after acquiring an additional 131 shares during the last quarter. Institutional investors and hedge funds own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $120.47 on Thursday. The stock has a market cap of $53.39 billion, a P/E ratio of 20.73, a PEG ratio of 2.31 and a beta of 0.90. The company’s 50-day simple moving average is $145.63 and its 200 day simple moving average is $153.01. Zoetis Inc. has a twelve month low of $119.07 and a twelve month high of $181.85. The company has a quick ratio of 1.04, a current ratio of 1.76 and a debt-to-equity ratio of 1.05.

Zoetis (NYSE:ZTS) last posted its earnings results on Tuesday, November 4th. The company reported $1.70 earnings per share for the quarter, beating analysts’ consensus estimates of $1.62 by $0.08. The business had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.42 billion. Zoetis had a net margin of 27.83% and a return on equity of 56.90%. The firm’s revenue for the quarter was up .5% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.58 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. As a group, research analysts forecast that Zoetis Inc. will post 6.07 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, December 2nd. Investors of record on Friday, October 31st will be paid a $0.50 dividend. The ex-dividend date of this dividend is Friday, October 31st. This represents a $2.00 dividend on an annualized basis and a yield of 1.7%. Zoetis’s payout ratio is presently 34.42%.

Analyst Ratings Changes

A number of research analysts have weighed in on ZTS shares. Argus reissued a “buy” rating and set a $190.00 target price on shares of Zoetis in a research report on Tuesday, September 9th. Weiss Ratings reissued a “hold (c-)” rating on shares of Zoetis in a research report on Wednesday, October 8th. Leerink Partnrs lowered shares of Zoetis from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 17th. JPMorgan Chase & Co. cut their price objective on shares of Zoetis from $230.00 to $200.00 and set an “overweight” rating for the company in a research report on Wednesday. Finally, Piper Sandler upped their price objective on shares of Zoetis from $210.00 to $215.00 and gave the company an “overweight” rating in a research report on Monday, August 11th. Five research analysts have rated the stock with a Buy rating and five have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $191.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.